Whole-exome sequencing reveals novel genetic variants associated with diverse phenotypes of melanoma cells

Melanoma: What do all the mutations mean?

(2018) Elizabeth J. Davis et al.   CANCER

Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics

(2018) Li Ding et al.   CELL

Comprehensive Characterization of Cancer Driver Genes and Mutations

(2018) Matthew H. Bailey et al.   CELL

Oncogenic Signaling Pathways in The Cancer Genome Atlas

(2018) Francisco Sanchez-Vega et al.   CELL

Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer

(2018) Katherine A. Hoadley et al.   CELL

MEK inhibition may increase survival of NRAS-mutated melanoma patients treated with checkpoint blockade: Results of a retrospective multicentre analysis of 364 patients

(2018) Michael Constantin Kirchberger et al.   EUROPEAN JOURNAL OF CANCER

The Immune Landscape of Cancer

(2018) Vésteinn Thorsson et al.   IMMUNITY

Molecular classification and subtype-specific characterization of skin cutaneous melanoma by aggregating multiple genomic platform data

(2018) Xiaofan Lu et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Dual-specificity phosphatase 6 genetic variants associated with risk of lung squamous cell carcinoma in Han Chinese

(2018) Yu-Xia Zhao et al.   Journal of Cancer Research and Therapeutics

Targeting insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) in metastatic melanoma to increase efficacy of BRAFV600E inhibitors

(2018) TaeWon Kim et al.   MOLECULAR CARCINOGENESIS

In vitro effects of FBXW7 mutation in serous endometrial cancer: Increased levels of potentially druggable proteins and sensitivity to SI-2 and dinaciclib

(2018) Mary Ellen Urick et al.   MOLECULAR CARCINOGENESIS

YAP/TAZ upstream signals and downstream responses

(2018) Antonio Totaro et al.   NATURE CELL BIOLOGY

AXL/AKT axis mediated-resistance to BRAF inhibitor depends on PTEN status in melanoma

(2018) Qiang Zuo et al.   ONCOGENE

FBXW7 regulates a mitochondrial transcription program by modulating MITF

(2018) Franco Abbate et al.   Pigment Cell & Melanoma Research

Regulation of senescence escape by the cdk4–EZH2–AP2M1 pathway in response to chemotherapy

(2018) Mélanie Le Duff et al.   Cell Death & Disease

Dual-specificity phosphatase 6 (DUSP6): a review of its molecular characteristics and clinical relevance in cancer

(2018) Khairi Ahmad Muhammad et al.   Cancer Biology & Medicine

Microenvironment-Driven Dynamic Heterogeneity and Phenotypic Plasticity as a Mechanism of Melanoma Therapy Resistance

(2018) Farzana Ahmed et al.   Frontiers in Oncology

The mitogen-activated protein kinase pathway in melanoma part I – Activation and primary resistance mechanisms to BRAF inhibition

(2017) Teresa Amaral et al.   EUROPEAN JOURNAL OF CANCER

Genetic variants in the genes encoding rho GTPases and related regulators predict cutaneous melanoma-specific survival

(2017) Shun Liu et al.   INTERNATIONAL JOURNAL OF CANCER

Identification of coexistence of BRAF V600E mutation and EZH2 gain specifically in melanoma as a promising target for combination therapy

(2017) Huan Yu et al.   Journal of Translational Medicine

Vemurafenib and trametinib reduce expression of CTGF and IL-8 in V600EBRAF melanoma cells

(2017) Mariusz L Hartman et al.   LABORATORY INVESTIGATION

P21-activated kinase 1 regulates resistance to BRAF inhibition in human cancer cells

(2017) Mahamat Babagana et al.   MOLECULAR CARCINOGENESIS

NF1-mutated melanoma tumors harbor distinct clinical and biological characteristics

(2017) Helena Cirenajwis et al.   Molecular Oncology

Whole-genome landscapes of major melanoma subtypes

(2017) Nicholas K. Hayward et al.   NATURE

Melanocytic nevi and melanoma: unraveling a complex relationship

(2017) W E Damsky et al.   ONCOGENE

Targeting Developmental Pathways: The Achilles Heel of Cancer?

(2017) Wolfram C.M. Dempke et al.   ONCOLOGY

FBXW7 inactivation in a Braf V600E -driven mouse model leads to melanoma development

(2017) Iraz T. Aydin et al.   Pigment Cell & Melanoma Research

Microenvironment-derived factors driving metastatic plasticity in melanoma

(2017) Isabella S. Kim et al.   Nature Communications

Inhibition of YAP function overcomes BRAF inhibitor resistance in melanoma cancer stem cells

(2017) Matthew L. Fisher et al.   Oncotarget

Systematic screening of isogenic cancer cells identifies DUSP6 as context-specific synthetic lethal target in melanoma

(2017) Stephanie Wittig-Blaich et al.   Oncotarget

YAP-Dependent AXL Overexpression Mediates Resistance to EGFR Inhibitors in NSCLC

(2017) Elena Ghiso et al.   NEOPLASIA

Exogenous growth factors bFGF, EGF and HGF do not influence viability and phenotype of V600EBRAF melanoma cells and their response to vemurafenib and trametinib in vitro

(2017) Izabela Zalesna et al.   PLoS One

The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma

(2016) Alex Kim et al.   Expert Opinion on Drug Discovery

p16INK4Ainduces senescence and inhibits EMT through microRNA-141/microRNA-146b-5p-dependent repression of AUF1

(2016) Huda H. Al-Khalaf et al.   MOLECULAR CARCINOGENESIS

An oncogenic Ezh2 mutation induces tumors through global redistribution of histone 3 lysine 27 trimethylation

(2016) George P Souroullas et al.   NATURE MEDICINE

EZH2 as a mediator of treatment resistance in melanoma

(2016) Jessamy C. Tiffen et al.   Pigment Cell & Melanoma Research

Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq

(2016) I. Tirosh et al.   SCIENCE

Targeting Notch enhances the efficacy of ERK inhibitors in BRAF-V600E melanoma

(2016) Clemens Krepler et al.   Oncotarget

Somatic Copy Number Amplification and Hyperactivating Somatic Mutations of EZH2 Correlate With DNA Methylation and Drive Epigenetic Silencing of Genes Involved in Tumor Suppression and Immune Responses in Melanoma

(2016) Jessamy Tiffen et al.   NEOPLASIA

Genomic Classification of Cutaneous Melanoma

(2015) Rehan Akbani et al.   CELL

Pro-Survival Role of MITF in Melanoma

(2015) Mariusz L. Hartman et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Phenotypic diversity of patient-derived melanoma populations in stem cell medium

(2015) Malgorzata Sztiller-Sikorska et al.   LABORATORY INVESTIGATION

The Ezh2 polycomb group protein drives an aggressive phenotype in melanoma cancer stem cells and is a target of diet derived sulforaphane

(2015) Matthew L. Fisher et al.   MOLECULAR CARCINOGENESIS

The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies

(2015) Luping Lin et al.   NATURE GENETICS

Germline determinants of clinical outcome of cutaneous melanoma

(2015) Matjaz Vogelsang et al.   Pigment Cell & Melanoma Research

The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors

(2015) Daniel Zingg et al.   Nature Communications

Mutant HRAS as novel target for MEK and mTOR inhibitors

(2015) Michael K. Kiessling et al.   Oncotarget

Inhibition of ERK1/2 down-regulates the Hippo/YAP signaling pathway in human NSCLC cells

(2015) Bin You et al.   Oncotarget

The Molecular Pathology of Melanoma: An Integrated Taxonomy of Melanocytic Neoplasia

(2014) Boris C. Bastian   Annual Review of Pathology-Mechanisms of Disease

Tumor Suppression by the Fbw7 Ubiquitin Ligase: Mechanisms and Opportunities

(2014) Ryan J. Davis et al.   CANCER CELL

Preexisting MEK1P124 Mutations Diminish Response to BRAF Inhibitors in Metastatic Melanoma Patients

(2014) M. S. Carlino et al.   CLINICAL CANCER RESEARCH

Axl mediates tumor invasion and chemosensitivity through PI3K/Akt signaling pathway and is transcriptionally regulated by slug in breast carcinoma

(2014) Yanyan Li et al.   IUBMB LIFE

FBXW7 Mutations in Melanoma and a New Therapeutic Paradigm

(2014) Iraz T. Aydin et al.   JNCI-Journal of the National Cancer Institute

Tumor heterogeneity and plasticity as elusive drivers for resistance to MAPK pathway inhibition in melanoma

(2014) A Roesch   ONCOGENE

Gene Expression Profiling Identifies Microphthalmia-Associated Transcription Factor (MITF) and Dickkopf-1 (DKK1) as Regulators of Microenvironment-Driven Alterations in Melanoma Phenotype

(2014) Mariusz L. Hartman et al.   PLoS One

Systematic identification of signaling pathways with potential to confer anticancer drug resistance

(2014) C. A. Martz et al.   Science Signaling

Complex Tumor Genomes Inferred from Single Circulating Tumor Cells by Array-CGH and Next-Generation Sequencing

(2013) E. Heitzer et al.   CANCER RESEARCH

 -arrestin 1 (ARRDC1) and  -arrestins cooperate to mediate Notch degradation in mammals

(2013) L. Puca et al.   JOURNAL OF CELL SCIENCE

The Role of the Hippo Pathway in Melanocytes and Melanoma

(2013) Ji Eun Kim et al.   Frontiers in Oncology

A Landscape of Driver Mutations in Melanoma

(2012) Eran Hodis et al.   CELL

Notch Signaling Promotes Growth and Invasion in Uveal Melanoma

(2012) L. Asnaghi et al.   CLINICAL CANCER RESEARCH

Plasticity of melanoma cells induced by neural cell crest conditions and three-dimensional growth

(2012) Stephanie Ghislin et al.   MELANOMA RESEARCH

Sphere formation and self-renewal capacity of melanoma cells is affected by the microenvironment

(2012) Malgorzata Sztiller-Sikorska et al.   MELANOMA RESEARCH

High Expression of Wee1 Is Associated with Poor Disease-Free Survival in Malignant Melanoma: Potential for Targeted Therapy

(2012) Gry Irene Magnussen et al.   PLoS One

Preexisting MEK1 Exon 3 Mutations in V600E/K BRAF Melanomas Do Not Confer Resistance to BRAF Inhibitors

(2012) Hubing Shi et al.   Cancer Discovery

Taxol Resistance in Breast Cancer Cells Is Mediated by the Hippo Pathway Component TAZ and Its Downstream Transcriptional Targets Cyr61 and CTGF

(2011) D. Lai et al.   CANCER RESEARCH

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

EZH2-Dependent Suppression of a Cellular Senescence Phenotype in Melanoma Cells by Inhibition of p21/CDKN1A Expression

(2011) T. Fan et al.   MOLECULAR CANCER RESEARCH

A Melanoma Molecular Disease Model

(2011) Smruti J. Vidwans et al.   PLoS One

C-MYC overexpression is required for continuous suppression of oncogene-induced senescence in melanoma cells

(2008) D Zhuang et al.   ONCOGENE